Monivent (MONI) Q2 2024 earnings summary

Executive summary

• Strengthened clinical evidence, intensive regulatory work, and a letter of intent for a global distribution agreement with a market leader create new conditions for commercial breakthrough.

• Clinical study published in Resuscitation shows significant improvement in manual ventilation quality with Neo100, supporting commercialization and potential guideline changes.

• Regulatory processes for FDA (USA) and MDR (Europe) are progressing, with approvals expected in early 2025.

• Cost structure adjustments have been made to accelerate profitability, with focus on reducing indirect costs and unlocking inventory value.

Financial highlights

• Net sales for Q2 2024 were 764 KSEK, down from 1,208 KSEK in Q2 2023; H1 2024 net sales were 1,224 KSEK, down from 1,608 KSEK year-over-year.

• EBIT for Q2 2024 was -2,907 KSEK (vs. -3,468 KSEK Q2 2023); H1 2024 EBIT was -5,966 KSEK (vs. -7,823 KSEK H1 2023).

• Cash and cash equivalents at period end were 1,874 KSEK, down from 5,703 KSEK a year earlier.

• Equity ratio at period end was 52%, compared to 69% at the end of H1 2023.

• Earnings per share for H1 2024 were -0.29 SEK, compared to -0.77 SEK for H1 2023.

Outlook and guidance

• FDA approval for the US market and MDR certification in Europe are expected in early 2025, enabling broader commercialization.

• Global distribution agreement with a leading neonatal and intensive care company is anticipated to accelerate market expansion, especially in the US.

• Ongoing cost reductions and inventory optimization are expected to strengthen the financial position in H2 2024.